<DOC>
	<DOCNO>NCT01858363</DOCNO>
	<brief_summary>This prospective , randomize , multi-center , single-blind study demonstrate safety effectiveness CVI Paclitaxel-coated percutaneous transluminal angioplasty ( PTA ) balloon versus bare PTA balloon treatment patient de novo occluded/stenotic reoccluded/restenotic lesion superficial femoral ( SFA ) popliteal artery .</brief_summary>
	<brief_title>CVI Drug Coated Balloon European Randomized Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Symptomatic leg ischemia require treatment superficial femoral popliteal artery Rutherford clinical category 2 , 3 4 Male nonpregnant female least 18 year Coexisting clinically significant aneurismal disease abdominal aorta , iliac popliteal artery Significant gastrointestinal bleeding coagulopathy would contraindicate use antiplatelet therapy Known intolerance study medication , paclitaxel contrast agent Active participation another investigational device drug study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Peripheral arterial disease</keyword>
	<keyword>claudication</keyword>
	<keyword>drug-coated balloon</keyword>
	<keyword>drug-eluting balloon</keyword>
</DOC>